XML 139 R115.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016
Segment Reporting Information [Line Items] |  |  |
Sales | $ 42,294 | $ 40,122 | $ 39,807
Proceeds from sale of intangible assets | 95 | 85 | 170
Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 42,151 | 39,662 | 39,014
Operating Segments | Pharmaceutical segment |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 37,689 | 35,390 | 35,151
Operating Segments | Pharmaceutical segment | Keytruda |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 7,171 | 3,809 | 1,402
Operating Segments | Pharmaceutical segment | Emend |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 522 | 556 | 549
Operating Segments | Pharmaceutical segment | Temodar |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 214 | 271 | 283
Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 187 | 20 | 0
Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 149 | 0 | 0
Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,151 | 2,308 | 2,173
Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,798 | 1,676 | 1,640
Operating Segments | Pharmaceutical segment | Pneumovax 23 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 907 | 821 | 641
Operating Segments | Pharmaceutical segment | RotaTeq |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 728 | 686 | 652
Operating Segments | Pharmaceutical segment | Zostavax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 217 | 668 | 685
Operating Segments | Pharmaceutical segment | Bridion |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 917 | 704 | 482
Operating Segments | Pharmaceutical segment | Noxafil |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 742 | 636 | 595
Operating Segments | Pharmaceutical segment | Invanz |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 496 | 602 | 561
Operating Segments | Pharmaceutical segment | Cubicin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 367 | 382 | 1,087
Operating Segments | Pharmaceutical segment | Cancidas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 326 | 422 | 558
Operating Segments | Pharmaceutical segment | Primaxin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 265 | 280 | 297
Operating Segments | Pharmaceutical segment | Simponi |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 893 | 819 | 766
Operating Segments | Pharmaceutical segment | Remicade |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 582 | 837 | 1,268
Operating Segments | Pharmaceutical segment | Belsomra |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 260 | 210 | 154
Operating Segments | Pharmaceutical segment | Isentress/Isentress HD |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,140 | 1,204 | 1,387
Operating Segments | Pharmaceutical segment | Zepatier |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 455 | 1,660 | 555
Operating Segments | Pharmaceutical segment | Zetia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 857 | 1,344 | 2,560
Operating Segments | Pharmaceutical segment | Vytorin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 497 | 751 | 1,141
Operating Segments | Pharmaceutical segment | Atozet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 347 | 225 | 146
Operating Segments | Pharmaceutical segment | Adempas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 329 | 300 | 169
Operating Segments | Pharmaceutical segment | Januvia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,686 | 3,737 | 3,908
Operating Segments | Pharmaceutical segment | Janumet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,228 | 2,158 | 2,201
Operating Segments | Pharmaceutical segment | NuvaRing |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 902 | 761 | 777
Operating Segments | Pharmaceutical segment | Implanon/Nexplanon |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 703 | 686 | 606
Operating Segments | Pharmaceutical segment | Singulair |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 708 | 732 | 915
Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 453 | 484 | 511
Operating Segments | Pharmaceutical segment | Nasonex |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 376 | 387 | 537
Operating Segments | Pharmaceutical segment | Arcoxia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 335 | 363 | 450
Operating Segments | Pharmaceutical segment | Follistim AQ |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 268 | 298 | 355
Operating Segments | Pharmaceutical segment | Dulera |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 214 | 287 | 436
Operating Segments | Pharmaceutical segment | Fosamax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 209 | 241 | 284
Operating Segments | Pharmaceutical segment | Other pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 4,090 | 4,065 | 4,420
Operating Segments | Animal Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 4,212 | 3,875 | 3,478
Operating Segments | Animal Health | Livestock |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,630 | 2,484 | 2,287
Operating Segments | Animal Health | Companion Animals |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,582 | 1,391 | 1,191
Operating Segments | Other segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 250 | 397 | 385
Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 143 | 460 | 793
United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 18,212 | 17,424 | 18,478
United States | Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 18,094 | 17,340 | 18,447
United States | Operating Segments | Pharmaceutical segment |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 16,608 | 15,854 | 17,073
United States | Operating Segments | Pharmaceutical segment | Keytruda |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 4,150 | 2,309 | 792
United States | Operating Segments | Pharmaceutical segment | Emend |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 312 | 342 | 356
United States | Operating Segments | Pharmaceutical segment | Temodar |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 6 | 16 | 15
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 127 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 95 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,873 | 1,565 | 1,780
United States | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,430 | 1,374 | 1,362
United States | Operating Segments | Pharmaceutical segment | Pneumovax 23 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 627 | 581 | 447
United States | Operating Segments | Pharmaceutical segment | RotaTeq |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 496 | 481 | 482
United States | Operating Segments | Pharmaceutical segment | Zostavax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 22 | 422 | 518
United States | Operating Segments | Pharmaceutical segment | Bridion |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 386 | 239 | 77
United States | Operating Segments | Pharmaceutical segment | Noxafil |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 353 | 309 | 284
United States | Operating Segments | Pharmaceutical segment | Invanz |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 253 | 361 | 329
United States | Operating Segments | Pharmaceutical segment | Cubicin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 191 | 189 | 906
United States | Operating Segments | Pharmaceutical segment | Cancidas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 12 | 20 | 25
United States | Operating Segments | Pharmaceutical segment | Primaxin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 7 | 10 | 4
United States | Operating Segments | Pharmaceutical segment | Simponi |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Remicade |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Belsomra |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 96 | 98 | 84
United States | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 513 | 565 | 721
United States | Operating Segments | Pharmaceutical segment | Zepatier |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 8 | 771 | 488
United States | Operating Segments | Pharmaceutical segment | Zetia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 45 | 352 | 1,588
United States | Operating Segments | Pharmaceutical segment | Vytorin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 10 | 124 | 473
United States | Operating Segments | Pharmaceutical segment | Atozet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 1
United States | Operating Segments | Pharmaceutical segment | Adempas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Januvia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,969 | 2,153 | 2,286
United States | Operating Segments | Pharmaceutical segment | Janumet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 811 | 863 | 984
United States | Operating Segments | Pharmaceutical segment | NuvaRing |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 722 | 564 | 576
United States | Operating Segments | Pharmaceutical segment | Implanon/Nexplanon |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 495 | 496 | 420
United States | Operating Segments | Pharmaceutical segment | Singulair |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 20 | 40 | 40
United States | Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 23 | 18 | 16
United States | Operating Segments | Pharmaceutical segment | Nasonex |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 23 | 54 | 184
United States | Operating Segments | Pharmaceutical segment | Arcoxia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Follistim AQ |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 115 | 123 | 157
United States | Operating Segments | Pharmaceutical segment | Dulera |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 186 | 261 | 412
United States | Operating Segments | Pharmaceutical segment | Fosamax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 4 | 6 | 5
United States | Operating Segments | Pharmaceutical segment | Other pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,228 | 1,148 | 1,261
United States | Operating Segments | Animal Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,238 | 1,090 | 989
United States | Operating Segments | Animal Health | Livestock |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 528 | 471 | 446
United States | Operating Segments | Animal Health | Companion Animals |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 710 | 619 | 543
United States | Operating Segments | Other segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 248 | 396 | 385
United States | Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 118 | 84 | 31
Int’l |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 24,083 | 22,698 | 21,329
Int’l | Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 24,057 | 22,322 | 20,566
Int’l | Operating Segments | Pharmaceutical segment |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 21,081 | 19,536 | 18,077
Int’l | Operating Segments | Pharmaceutical segment | Keytruda |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,021 | 1,500 | 610
Int’l | Operating Segments | Pharmaceutical segment | Emend |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 210 | 213 | 193
Int’l | Operating Segments | Pharmaceutical segment | Temodar |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 209 | 256 | 268
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 61 | 20 | 0
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 54 | 0 | 0
Int’l | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,279 | 743 | 393
Int’l | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 368 | 303 | 279
Int’l | Operating Segments | Pharmaceutical segment | Pneumovax 23 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 281 | 240 | 193
Int’l | Operating Segments | Pharmaceutical segment | RotaTeq |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 232 | 204 | 169
Int’l | Operating Segments | Pharmaceutical segment | Zostavax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 195 | 246 | 168
Int’l | Operating Segments | Pharmaceutical segment | Bridion |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 531 | 465 | 405
Int’l | Operating Segments | Pharmaceutical segment | Noxafil |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 389 | 327 | 312
Int’l | Operating Segments | Pharmaceutical segment | Invanz |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 243 | 241 | 233
Int’l | Operating Segments | Pharmaceutical segment | Cubicin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 176 | 193 | 181
Int’l | Operating Segments | Pharmaceutical segment | Cancidas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 314 | 402 | 533
Int’l | Operating Segments | Pharmaceutical segment | Primaxin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 258 | 270 | 293
Int’l | Operating Segments | Pharmaceutical segment | Simponi |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 893 | 819 | 766
Int’l | Operating Segments | Pharmaceutical segment | Remicade |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 582 | 837 | 1,268
Int’l | Operating Segments | Pharmaceutical segment | Belsomra |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 164 | 112 | 70
Int’l | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 627 | 639 | 666
Int’l | Operating Segments | Pharmaceutical segment | Zepatier |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 447 | 888 | 67
Int’l | Operating Segments | Pharmaceutical segment | Zetia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 813 | 992 | 972
Int’l | Operating Segments | Pharmaceutical segment | Vytorin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 487 | 627 | 668
Int’l | Operating Segments | Pharmaceutical segment | Atozet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 347 | 225 | 146
Int’l | Operating Segments | Pharmaceutical segment | Adempas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 329 | 300 | 169
Int’l | Operating Segments | Pharmaceutical segment | Januvia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,718 | 1,584 | 1,622
Int’l | Operating Segments | Pharmaceutical segment | Janumet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,417 | 1,296 | 1,217
Int’l | Operating Segments | Pharmaceutical segment | NuvaRing |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 180 | 197 | 202
Int’l | Operating Segments | Pharmaceutical segment | Implanon/Nexplanon |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 208 | 191 | 186
Int’l | Operating Segments | Pharmaceutical segment | Singulair |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 688 | 692 | 874
Int’l | Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 431 | 466 | 494
Int’l | Operating Segments | Pharmaceutical segment | Nasonex |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 353 | 333 | 352
Int’l | Operating Segments | Pharmaceutical segment | Arcoxia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 335 | 363 | 450
Int’l | Operating Segments | Pharmaceutical segment | Follistim AQ |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 153 | 174 | 197
Int’l | Operating Segments | Pharmaceutical segment | Dulera |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 28 | 26 | 24
Int’l | Operating Segments | Pharmaceutical segment | Fosamax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 205 | 235 | 279
Int’l | Operating Segments | Pharmaceutical segment | Other pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,855 | 2,917 | 3,158
Int’l | Operating Segments | Animal Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,974 | 2,785 | 2,489
Int’l | Operating Segments | Animal Health | Livestock |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,102 | 2,013 | 1,841
Int’l | Operating Segments | Animal Health | Companion Animals |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 872 | 772 | 648
Int’l | Operating Segments | Other segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2 | 1 | 0
Int’l | Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | $ 26 | $ 376 | $ 763

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_TemodarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZostavaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DuleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FosamaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |